Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract CancersRachna T. Shroff, Mitesh J. Borad, Milind Javle et al.|JAMA Oncology|2019Cited by 472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 studyMilind Javle, Ghassan K. Abou‐Alfa, Sameek Roychowdhury et al.|The Lancet. Gastroenterology & hepatology|2021Cited by 423
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b studyJames J. Harding, Sebastián Mondaca, Dong Uk Kim et al.|The Lancet Oncology|2023Cited by 243
HER2/neu-directed therapy for biliary tract cancerMilind Javle, Abby B. Siegel|Journal of Hematology & Oncology|2015Cited by 223
A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal AdenocarcinomaEugene J. Koay, Jason B. Fleming, Yeon‐Ju Lee et al.|Clinical Cancer Research|2018Cited by 111